FOR HEALTHCARE PROFESSIONALS


The Nasal Allergy Symptom Relief of XYZAL®

Approved by the FDA, XYZAL is now indicated for the relief of symptoms associated with perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older, and in the relief of symptoms associated with seasonal allergic rhinitis in adults and children 2 years of age and older.

POTENT

  •  Potent inhibition of histamine-induced wheal and flare
    •  The clinical relevance of histamine skin testing is unknown

CONSISTENT

  1.  Consistent efficacy across 8 clinical trials
    1.  Six clinical trials in allergic rhinitis (seasonal and perennial; patients ≥12 years of age)
    2.  Two clinical trials in chronic idiopathic urticaria
      (patients ≥18 years of age)

FAST AND LONG-LASTING

  •  Onset of efficacy was seen at 60 minutes and efficacy was demonstrated at the end of the 24-hour dosing interval (EEU* study)

PROVEN SAFETY PROFILE


CONVENIENT ONCE-DAILY PM DOSING

*EEU = Environmental Exposure Unit

LEARN THE XYZs OF XYZAL

Doctor

Great News for Kids!

XYZAL® now offers nasal allergy symptom relief for children age 6 months and older with year-round allergies and chronic hives!
Learn More »

Indications

XYZAL® (levocetirizine dihydrochloride) is indicated for the relief of symptoms associated with perennial allergic rhinitis and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 months of age and older, and for relief of symptoms of seasonal allergic rhinitis in adults and children 2 years of age and older.

Important Safety Information

The use of XYZAL is contraindicated in: patients with a known hypersensitivity to levocetirizine or any of the ingredients of XYZAL or to cetirizine (observed reactions range from urticaria to anaphylaxis); patients with end-stage renal disease with a creatinine clearance less than 10 mL/min or patients undergoing hemodialysis; and pediatric patients aged 6 months to 11 years with renal impairment.

Patients should be cautioned against engaging in hazardous occupations requiring complete mental alertness such as driving or operating machinery when taking XYZAL. Concurrent use of XYZAL with alcohol or other central nervous system (CNS) depressants should be avoided. In clinical trials, the most common adverse reactions in ≥2% of adult and adolescent patients (12 years of age and older) taking XYZAL 2.5 mg or XYZAL 5 mg once daily or placebo were somnolence (5%, 6%, 2%), nasopharyngitis (6%, 4%, 3%), fatigue (1%, 4%, 2%), dry mouth (3%, 2%, 1%), and pharyngitis (2%, 1%, 1%), respectively.

In clinical trials, the most common adverse reactions in ≥2% of pediatric patients 6 to 12 years of age taking XYZAL 5 mg once daily or placebo were pyrexia (4%, 2%), cough (3%, <1%), somnolence (3%, <1%), and epistaxis (2%, <1%), respectively. The most common adverse reactions in ≥2% of pediatric patients 1 to 5 years of age taking XYZAL 1.25 mg twice daily or placebo were pyrexia (4%, 2%), diarrhea (4%, 3%), vomiting (4%, 3%), and otitis media (3%, 0%), respectively. The most common adverse reactions in pediatric patients 6 to 11 months of age taking XYZAL 1.25 mg once daily or placebo were diarrhea (13%, 4%) and constipation (7%, 4%), respectively.

XYZAL is a trademark of UCB Group of companies.
© 2009 UCB, Inc. and sanofi-aventis U.S. LLC. All rights reserved. X1257-1109
Last Updated: January 2010